On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- 5 Insights From The 2025 JP Morgan Healthcare Conference (Forbes)
- Clinicians turned to contract work to escape the grind. They’re finding the same challenges (Path to Recovery)
- Exact Sciences Announces Preliminary Fourth Quarter 2024 Results (Business Wire)
- New Oshi Health Report Documents Impact of Its Hybrid Multidisciplinary GI Care (PR Newswire)
- High cost of colonoscopy deterring young Americans from testing—and raising cancer risk (BMJ)
- Experts Argue It’s Time for Obesity to Be Defined Beyond BMI (TIME)
- Prioritizing Blood-Based Colorectal Cancer Tests May Lead to Higher Costs, Worse Outcomes (AJMC)
- Arif Kamal: Nearly 40% of colon cancers are attributable to sub-optimal diet (OncoDaily)
